BNP/NT-proBNP、sST2与肺动脉高压研究进展

摘要/Abstract

摘要： 肺动脉高压（pulmonary arterial hypertension,PAH）是一种由多种原因导致肺动脉压力进行性升高,最终导致右心衰竭甚至死亡的严重心血管疾病。近年来,针对PAH发病机制而研发的多种靶向药物的使用,在一定程度上延缓了该类患者的病情进展,但其远期预后形式仍相当严峻。因此,寻找与病情严重程度密切相关,能对疾病近期及远期预后做出准确预测的生物标记物显得尤为重要。目前为止,血浆脑钠肽（BNP）和N端脑钠肽前体（NT-proBNP）被证明能在相当程度上反应疾病严重程度及评估预后。但可溶性肿瘤抑制体2（sST2）,作为新一代心衰生物标记物,被认为能更客观准确地评价疾病严重程度及评估预后。现对BNP/NT-proBNP、sST2与PAH研究进展作简要综述。

关键词: 肺动脉高压, 血浆脑钠肽/N端脑钠肽前体, 可溶性肿瘤抑制体2, 预后

Abstract: Pulmonary arterial hypertension（PAH） is a serious cardiovascular disease that causes progressive elevation of pulmonary artery pressure for a number of reasons, eventually leading to right heart failure and even death. In recent years, the use of targeted drugs developed for the pathogenesis of PAH has delayed the progress of this kind of patients to some extent, but its long-term prognosis is still very severe. Therefore, it is particularly important to find biomarkers which are closely related to the severity of the disease and can accurately predict the short-term and long-term prognosis of the disease. So far, brain natriuretic peptide（BNP）and N-terminal pro-brain natriuretic peptide (NT-proBNP) has been proved to reflect the severity and prognosis of the disease to a considerable extent, but soluble suppression of tumorigenicity 2 (sST2), as a new generation plasma marker of heart failure, is considered to be more objective and accurate to evaluate the severity and prognosis of the disease. In this paper, the research progress of BNP/NT-proBNP and sST2 in PAH is briefly reviewed.

Key words: Pulmonary arterial hypertension, BNP/NT-proBNP, sST2, Prognosis

梁志斌, 姚桦. BNP/NT-proBNP、sST2与肺动脉高压研究进展[J]. 心血管病防治知识, 2021, 11(32): 67-72.

LIANG Zhi-bin, YAO Hua. Research progress on the relationship between BNP/NT-proBNP、sST2 and pulmonary arterial hypertension[J]. Prevention and Treatment of Cardiovascular Disease, 2021, 11(32): 67-72.

参考文献

[1] Adaani, et al. Diagnosis of pulmonary hypertension[J].
[2] Galiè N.2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)[J]. European heart journal, 2016,37(1): 67-119.
[3] Simonneau G.Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J]. The European respiratory journal, 2019,53(1): 1801913.
[4] 中国肺动脉高压诊断与治疗指南(2021版)[J].中华医学杂志,2021,101(1):11-51.
[5] McLaughlin VV. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association[J]. Journal of the American College of Cardiology, 2009,53(17): 1573-1619.
[6] Galiè N.An overview of the 6th World Symposium on Pulmonary Hypertension[J]. Eur Respir J, 2019, 53(1).
[7] McGlinchey N and MK Johnson. Novel serum biomarkers in pulmonary arterial hypertension[J]. Biomarkers in medicine, 2014,8(8):1001-1011.
[8] Yancy CW.2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. Circulation, 2013,128(16): 1810-1852.
[9] McDonagh TA. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021,42(36):3599-3726.
[10] Goetze JP.Atrial natriuretic peptides in plasma[J]. Clinica chimica acta; international journal of clinical chemistry, 2015,443: 25-28.
[11] S.Rafeq, A. M.Shah and I. R.Preston. Biomarkers in pulmonary arterial hypertension[J]. International Journal of Clinical Practice Supplement, 2009,63(162): 36-41.
[12] Lemos JAD, DK Mcguire and MH Drazner. B-type natriuretic peptide in cardiovascular disease[J]. Lancet, 2003,362(9380): 316-322.
[13] Galiè N.Risk stratification and medical therapy of pulmonary arterial hypertension[J]. The European respiratory journal, 2019, 53(1): 1801889.
[14] Nagaya N.Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension[J]. Circulation, 2000,102(8): 865-870.
[15] Leuchte HH.N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension[J]. Chest, 2007,131(2): 402-409.
[16] Wilkins MR.Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study[J]. Am J Respir Crit Care Med,171(11): 1292-1297.
[17] Fijalkowska A.Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension[J]. Chest, 2006,129(5): 1313-1321.
[18] Mauritz G-J.Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension[J]. The American journal of cardiology, 2011,108(11): 1645-1650.
[19] Souza R.NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension[J]. Respiratory medicine, 2007, 101(1): 69-75.
[20] Souza R.Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension[J]. Current medical research and opinion, 2005,21(6): 907-911.
[21] Souza R.The role of NT-proBNP as a prognostic marker in pulmonary hypertension[J]. Chest, 2006,130(5): 1627-1628.
[22] Allanore Y.High N‐terminal pro–brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis[J]. 2008, 58(1):284-291.
[23] Williams and M. H. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension[J]. European Heart Journal,27(12): 1485-1494.
[24] Shapiro S.Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1)[J]. Respiratory medicine, 2017, 126: 84-92.
[25] McLaughlin VV. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial[J]. Journal of the American College of Cardiology, 2010,55(18): 1915-1922.
[26] Galiè N.Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension[J]. The New England journal of medicine, 2015,373(9): 834-844.
[27] Galie N.SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension[J]. Eur Heart J,2017, 38:1147-1155.
[28] Chin KM.Association of N-terminal pro brain natriuretic peptide and long-term out-come in patients with pulmonary arterial hypertension[J]. Circulation,2019, 139: 2440-2450.
[29] Kakkar R and RT Lee, The IL-33/ST2 pathway: therapeutic target and novel biomarker[J]. Nature Reviews Drug Discovery,7(10): 827-840.
[30] Schmitz J.IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines[J]. 23(5): 0-490.
[31] Ky B.High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure[J]. Circulation Heart Failure, 4(2): 180-187.
[32] Shao D.Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension[J].Biochemical and biophysical research communications, 2014,451(1): p. 8-14.
[33] Demyanets S.Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature[J]. Journal of Molecular & Cellular Cardiology, 60: 16-26.
[34] Tung YC and PH. Chu. Soluble ST2: A Novel Prognostic Biomarker of Heart Failure[J]. Acta Cardiologica Sinica, 2014,30(5): 501-503.
[35] Dieplinger B,Egger M,Haltmayer M,et al.Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study[J].Clin Chem,2014,60(3):530-540.
[36] Wernly B.Soluble ST2 predicts 1-year outcome in patients undergoing transcatheter aortic valve implantation[J]. European Journal of Clinical Investigation,47(2): 149-157.
[37] Wang GL,Liu Sh,Wang L,et al.The expression of IL33/ST2 in congenital pulmonary hypertension[J]. Cardiology,2014. 2014,129:43.
[38] Zheng Y-G.Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension[J]. Clinical cardiology, 2014,37(6): 365-370.
[39] Geenen LW.The Prognostic Value of Soluble ST2 in Adults with Pulmonary Hypertension[J]. Journal of clinical medicine, 2019,8(10): 1517.
[40] Agoston-Coldea L.Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction[J]. Biomarkers in medicine, 2014. 8(1): 95-106.
[41] Carlomagno G.Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension[J]. International Journal of Cardiology, 2013,168(2):1545-1547.
[42] Soluble ST2 Plasma Concentrations Predict 1-Year Mortality in Acutely Dyspneic Emergency Department Patients With Pulmonary Disease[J]. American Journal of Clinical Pathology,130(4): 578-584.
[43] Contractor J.Soluble ST2 is affected by pulmonary hypertension severity in patients undergoing cardiac resynchronization therapy[J]. Journal of the American College of Cardiology, 2016,67(13).
[44] Mirna M,Rohm I,Jira P,et al.Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH)[J]. Heart, Lung and Circulation, 2020,29(3):337-344.
[45] Pascual-Figal DA.Clinical relevance of sST2 in cardiac diseases[J]. Clinical chemistry and laboratory medicine, 2016,54(1): 29-35.
[46] 黄静. ST2在心血管疾病方面研究新进展[J]. 中国医学创新, 2016. 13(25): 87-89.
[47] Chida A,Sato H,Shintani M,et al.Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Useful biomarker for predicting outcome of childhoodpulmonary arterial hypertension[J]. Circulation journal : official journal of the Japanese Circulation Society, 2014,78(2):436-442.
[48] Scherzer R,Shah SJ,Secernsky E,et al.Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection[J].circ·Heart Fail,2018,11(4):e004312.
[49] Rui P.Prognostic stratification in pulmonary hypertension: a multibiomarker approach. in 20th World Congress on Heart Disease. 2015.